# GLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases

**Authors:** Kuan-Yu Chi, Yu Chang, Junmin Song, Chien-Min Chen, Pang-Shuo Perng, Hong-Min Lin

PMC · DOI: 10.1001/jamanetworkopen.2026.1311 · JAMA Network Open · 2026-03-11

## TL;DR

This study examines if using GLP-1 receptor agonists affects survival in type 2 diabetes patients with brain metastases.

## Contribution

It explores the novel association between GLP-1 RA use and survival outcomes in this specific patient population.

## Key findings

- The study evaluates survival rates among patients using GLP-1 receptor agonists.
- It investigates whether GLP-1 RA use is associated with improved or worsened survival in patients with brain metastases.
- Findings may inform treatment strategies for type 2 diabetes patients with brain metastases.

## Abstract

This cohort study assesses the association between glucagon-like peptide–1 receptor agonist (GLP-1 RA) use and survival in patients with type 2 diabetes and brain metastases.

## Linked entities

- **Diseases:** type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}
- **Diseases:** Type 2 Diabetes (MESH:D003924), Brain Metastases (MESH:D001932)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12980253/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12980253/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC12980253/full.md

---
Source: https://tomesphere.com/paper/PMC12980253